Hepatitis C

Top Story

DAAs safe, effective for heart transplant recipients with HCV

September 18, 2017

Direct-acting antiviral therapies Harvoni and Daklinza plus Sovaldi were both safe and highly effective among patients with chronic hepatitis C virus infection who received heart transplants, researchers in Taiwan reported.

“The reported prevalence of HCV infection among heart transplant recipients ranges from 7% to 18%,” Jia-Horng Kao, MD, of the department of internal medicine at National Taiwan University Hospital, Taipei, and colleagues wrote. “The use of [interferon (IFN)-free] direct-acting antiviral agents (DAAs) has confirmed the excellent efficacy and safety for ordinary patients with chronic HCV infection. Till now, there are no case series to evaluate the effectiveness and safety of IFN-free DAAs for heart transplant recipients with chronic HCV infection.”

Meeting News

Transmission, reinfection common in prisoners with HCV who inject drugs

September 15, 2017
Hepatitis C transmission rates were high in Australian prisons and significantly correlated with injection drug use, according to a presentation at the International…
Meeting News

HCV therapy feasible in drug users receiving multidisciplinary care

September 14, 2017
People with hepatitis C virus infection and a recent or current history of drug use who were enrolled in a multidisciplinary care program responded well to direct-acting…

Treating HCV in PWID: New prospects for managing an elusive population

September 14, 2017
People who inject drugs have historically represented a population at high risk for hepatitis C virus. However, these patients are often wary of authority figures or…
More Headlines »
CME CE CNE CPE CPE

HIV/AIDS 1 Hour Update For Florida Health Professionals

No commercial support for this activity.

This is a 1 hour activity designed for home study by healthcare clinicians. Specifically, it meets the 1 hour HIV/AIDS…
More »
In the Journals Plus

DAAs safe, effective for heart transplant recipients with HCV

September 18, 2017
Direct-acting antiviral therapies Harvoni and Daklinza plus Sovaldi were both safe and highly effective among patients…
More »
Resource Centers
ASM Microbe

ASM Microbe

Video
Meeting News

VIDEO: Telemedicine aids treatment of patients with HCV, substance use disorders

April 23, 2017
More »
Advertisement
Advertisement